Form 8-K - Current report:
SEC Accession No. 0000950170-24-075760
Filing Date
2024-06-21
Accepted
2024-06-20 17:36:27
Documents
11
Period of Report
2024-06-20
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K acrv-20240620.htm   iXBRL 8-K 51704
  Complete submission text file 0000950170-24-075760.txt   172595

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acrv-20240620.xsd EX-101.SCH 26942
14 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20240620_htm.xml XML 5114
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 241057621
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)